140 related articles for article (PubMed ID: 10511590)
1. Antiangiogenic activity of prostate-specific antigen.
Fortier AH; Nelson BJ; Grella DK; Holaday JW
J Natl Cancer Inst; 1999 Oct; 91(19):1635-40. PubMed ID: 10511590
[TBL] [Abstract][Full Text] [Related]
2. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic properties of prostate-specific antigen (PSA).
Mattsson JM; Laakkonen P; Stenman UH; Koistinen H
Scand J Clin Lab Invest; 2009; 69(4):447-51. PubMed ID: 19551556
[TBL] [Abstract][Full Text] [Related]
4. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition.
Matsui J; Yamamoto Y; Funahashi Y; Tsuruoka A; Watanabe T; Wakabayashi T; Uenaka T; Asada M
Int J Cancer; 2008 Feb; 122(3):664-71. PubMed ID: 17943726
[TBL] [Abstract][Full Text] [Related]
5. Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects.
Li D; Xie K; Zhang L; Yao X; Li H; Xu Q; Wang X; Jiang J; Fang J
Cancer Lett; 2016 Jul; 377(2):164-73. PubMed ID: 27130666
[TBL] [Abstract][Full Text] [Related]
6. Peptides binding to prostate-specific antigen enhance its antiangiogenic activity.
Mattsson JM; Närvänen A; Stenman UH; Koistinen H
Prostate; 2012 Oct; 72(14):1588-94. PubMed ID: 22430591
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with viable human umbilical vein endothelial cells prevents metastatic tumors by attack on tumor vasculature with both cellular and humoral immunity.
Chen XY; Zhang W; Zhang W; Wu S; Bi F; Su YJ; Tan XY; Liu JN; Zhang J
Clin Cancer Res; 2006 Oct; 12(19):5834-40. PubMed ID: 17020991
[TBL] [Abstract][Full Text] [Related]
8. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
9. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
[TBL] [Abstract][Full Text] [Related]
10. Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches.
van Moorselaar RJ; Voest EE
Mol Cell Endocrinol; 2002 Nov; 197(1-2):239-50. PubMed ID: 12431818
[TBL] [Abstract][Full Text] [Related]
11. Enzymatic activity of free-prostate-specific antigen (f-PSA) is not required for some of its physiological activities.
Chadha KC; Nair BB; Chakravarthi S; Zhou R; Godoy A; Mohler JL; Aalinkeel R; Schwartz SA; Smith GJ
Prostate; 2011 Nov; 71(15):1680-90. PubMed ID: 21446007
[TBL] [Abstract][Full Text] [Related]
12. Alpha-tocopheryl succinate (alpha-TOS) modulates human prostate LNCaP xenograft growth and gene expression in BALB/c nude mice fed two levels of dietary soybean oil.
Basu A; Grossie B; Bennett M; Mills N; Imrhan V
Eur J Nutr; 2007 Feb; 46(1):34-43. PubMed ID: 17180484
[TBL] [Abstract][Full Text] [Related]
13. Anti-angiogenic activity of PSA-derived peptides.
Chadha KC; Nair B; Godoy A; Rajnarayanan R; Nabi E; Zhou R; Patel NR; Aalinkeel R; Schwartz SA; Smith GJ
Prostate; 2015 Sep; 75(12):1285-99. PubMed ID: 25963523
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of angiogenesis involves in anticancer activity of riccardin D, a macrocyclic bisbibenzyl, in human lung carcinoma.
Sun CC; Zhang YS; Xue X; Cheng YN; Liu HP; Zhao CR; Lou HX; Qu XJ
Eur J Pharmacol; 2011 Sep; 667(1-3):136-43. PubMed ID: 21704029
[TBL] [Abstract][Full Text] [Related]
15. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
[TBL] [Abstract][Full Text] [Related]
16. Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis.
Nie D; Lamberti M; Zacharek A; Li L; Szekeres K; Tang K; Chen Y; Honn KV
Biochem Biophys Res Commun; 2000 Jan; 267(1):245-51. PubMed ID: 10623605
[TBL] [Abstract][Full Text] [Related]
17. Doxazosin inhibits human vascular endothelial cell adhesion, migration, and invasion.
Keledjian K; Garrison JB; Kyprianou N
J Cell Biochem; 2005 Feb; 94(2):374-88. PubMed ID: 15526277
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activities of synthetic and natural stilbenes through antiangiogenic action.
Kimura Y; Sumiyoshi M; Baba K
Cancer Sci; 2008 Oct; 99(10):2083-96. PubMed ID: 19016770
[TBL] [Abstract][Full Text] [Related]
19. Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo.
Fortier AH; Holaday JW; Liang H; Dey C; Grella DK; Holland-Linn J; Vu H; Plum SM; Nelson BJ
Prostate; 2003 Aug; 56(3):212-9. PubMed ID: 12772191
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative.
Taraboletti G; Micheletti G; Rieppi M; Poli M; Turatto M; Rossi C; Borsotti P; Roccabianca P; Scanziani E; Nicoletti MI; Bombardelli E; Morazzoni P; Riva A; Giavazzi R
Clin Cancer Res; 2002 Apr; 8(4):1182-8. PubMed ID: 11948131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
